High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4+ T cell arrest on the inflamed BBB under flow in vitro
Sasha Soldati(University of Bern), Britta Engelhardt(University of Bern), Fabien Gosselet(Université d'Artois), Dale Glavin(University of Rochester), Mykhailo Vladymyrov(University of Bern), Hideaki Nishihara(University of Bern), Alexander Bär(University of Bern), James L. McGrath(University of Rochester Medicine), Susan Goelz(Biogen (United States))
Cited by 18
Related Papers
The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction
|Seminars in Immunopathology|2009|784
Charge- and size-based separation of macromolecules using ultrathin silicon membranes
|Nature|2007|754
The influence of protein adsorption on nanoparticle association with cultured endothelial cells
|Biomaterials|2008|408
Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
|Journal of Cerebral Blood Flow & Metabolism|2012|307
Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse
|Journal of Pharmacology and Experimental Therapeutics|2000|286